Home›Screener›PHAT›Profile
D
41/100

Phathom Pharmaceuticals

PHATGI
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Phathom Pharmaceuticals (PHAT) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 2[1].

No Form 4 insider filings for PHAT were recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR · 0001783183 (2026-04-11) ↗
🔬
Clinical Trials
2
NCT06660342Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06851559Eosinophilic Esophagitis
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials2
Sector Peers (GI)
AMTIApplied Molecular Transport
D
IRWDIronwood Pharmaceuticals
D
Data Provenance
cik1 verified
clinical trial2 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR